Passage BIO PASG 深 滬
已收盤 08-01 16:00:00 美东时间
5.74
-0.680
-10.59%
華盛通- 最 高6.3495
- 今 開6.29
- 成交量 4.89万股
- 最 低 5.60
- 昨 收 6.42
- 總市值 1791.05万
- 52周最高 26.60
- 市盈率 靜 --
- 換手率 1.57%
- 52周最低 5.1239
- 委 比 -71.59%
- 總股本 312.03万
- 歷史最高 764.60
- 量 比 0.37
- 振 幅 11.67%
- 歷史最低 5.14
- 每 手 1
- 風險率 0.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Passage Bio Regains Nasdaq Compliance with Stock Price
Passage Bio ( ($PASG) ) just unveiled an update. On July 28, 2025, Passage Bio,...
07-30 05:31
Passage Bio shares are trading lower after the company announced a 1-for-20 reverse stock split.
Passage Bio shares are trading lower after the company announced a 1-for-20 rev...
07-10 20:28
Passage Bio Announces 1-for-20 Reverse Stock Split
Passage Bio announced a 1-for-20 reverse stock split to regain compliance with Nasdaq's $1.00 bid price requirement. The split will reduce outstanding shares from ~62.4 million to ~3.12 million, effective July 14, 2025, under symbol "PASG." Fractional shares will be rounded up, and no action is needed by registered or street name holders. The Company’s equity plans and employee stock purchase plan will be adjusted accordingly, without affecting s...
07-10 11:00
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
Passage Bio Reports Interim Data From upliFT-D Showing Durable CSF PGRN Elevation And Reduced Plasma NfL Versus Natural History In FTD-GRN
PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural historyDose 2, 50% lower than Dose 1, substantially
06-23 19:07
Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
Passage Bio reported positive interim data from its Phase 1/2 upliFT-D trial of PBFT02 for FTD-GRN, showing sustained increases in CSF PGRN and reduced plasma NfL levels. The lower Dose 2 significantly elevated PGRN to near healthy levels. While safety concerns, including thrombosis and embolism, emerged, they were manageable. The company plans to amend protocols to enhance safety and optimize enrollment, targeting key regulatory milestones in 20...
06-23 11:00
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers TNF Pharmaceuticals (NASDAQ:TNFA) shares moved upwards by 19.6% to $0....
03-14 05:05
美股大行评级 | 富国银行：维持艾伯维"超配"评级，目标价从210美元升至240美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1104327819967434752.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Syndax制药(SNDX)"超配"评级，目标价从35美元升至39美元</p> <p>• 摩根大通：维持AnaptysBio(ANAB)"超配"评级，目标价从36美元升至42美元</p> <p>• 摩根大通
03-06 11:20
美股大行评级 | 美银证券：维持艾伯维"中性"评级，目标价从200美元升至223美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1103964892578983937.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Syndax制药(SNDX)"超配"评级，目标价从35美元升至39美元</p> <p>• 摩根大通：维持Apellis Pharmaceuticals(APLS)"超配"评级，目标价从50美元升至54美元</
03-05 09:55
硅鑫集团盘中涨近20%拟收购矿业公司 探明金矿潜在储量达1万吨
硅鑫集团（08349）早盘一度涨近20%，截至发稿，股价上涨17.02%，现报2.20港元，成交额700.97万港元。 近日，硅鑫集团发布公告，公告中提到公...
01-22 10:50
